Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study

Anton Hagenbeek; Hans Mooij; Josée Zijlstra; Pieternella Lugtenburg; Gustaaf van Imhoff; Marcel Nijland; Sanne Tonino; Martin Hutchings; Marjolein Spiering; Roberto Liu; Harm van Tinteren; Marie José Kersten

doi:10.3324/haematol.2018.196899

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study

Anton Hagenbeek
, Hans Mooij
, Josée Zijlstra
, Pieternella Lugtenburg
, Gustaaf van Imhoff
, Marcel Nijland
, Sanne Tonino
, Martin Hutchings
, Marjolein Spiering
, Roberto Liu
, Harm van Tinteren
, Marie José Kersten

Research output: Contribution to journal › Letter › peer-review

27 Citations (Scopus)

Original language	English
Pages (from-to)	e151-e153
Journal	Haematologica
Volume	104
Issue number	4
DOIs	https://doi.org/10.3324/haematol.2018.196899
Publication status	Published - 31 Mar 2019
Externally published	Yes

Access to Document

10.3324/haematol.2018.196899

Cite this

Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H., & Kersten, M. J. (2019). Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study. Haematologica, 104(4), e151-e153. https://doi.org/10.3324/haematol.2018.196899

@article{c26b32c32a97476c9eb142722b7e496f,

title = "Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study",

author = "Anton Hagenbeek and Hans Mooij and Jos{\'e}e Zijlstra and Pieternella Lugtenburg and \{van Imhoff\}, Gustaaf and Marcel Nijland and Sanne Tonino and Martin Hutchings and Marjolein Spiering and Roberto Liu and \{van Tinteren\}, Harm and Kersten, \{Marie Jos{\'e}\}",

note = "Funding Information: a HOVON/ LLPC study. Takeda Oncology USA financially supported this Investigator Initiated Study sponsored by the Academic Medical Center.",

year = "2019",

month = mar,

day = "31",

doi = "10.3324/haematol.2018.196899",

language = "English",

volume = "104",

pages = "e151--e153",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "4",

}

Hagenbeek, A, Mooij, H, Zijlstra, J, Lugtenburg, P, van Imhoff, G, Nijland, M, Tonino, S, Hutchings, M, Spiering, M, Liu, R, van Tinteren, H & Kersten, MJ 2019, 'Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study', Haematologica, vol. 104, no. 4, pp. e151-e153. https://doi.org/10.3324/haematol.2018.196899

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study. / Hagenbeek, Anton; Mooij, Hans; Zijlstra, Josée et al.
In: Haematologica, Vol. 104, No. 4, 31.03.2019, p. e151-e153.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma

T2 - The HOVON/LLPC transplant brave study

AU - Hagenbeek, Anton

AU - Mooij, Hans

AU - Zijlstra, Josée

AU - Lugtenburg, Pieternella

AU - van Imhoff, Gustaaf

AU - Nijland, Marcel

AU - Tonino, Sanne

AU - Hutchings, Martin

AU - Spiering, Marjolein

AU - Liu, Roberto

AU - van Tinteren, Harm

AU - Kersten, Marie José

N1 - Funding Information: a HOVON/ LLPC study. Takeda Oncology USA financially supported this Investigator Initiated Study sponsored by the Academic Medical Center.

PY - 2019/3/31

Y1 - 2019/3/31

UR - https://www.scopus.com/pages/publications/85063979631

U2 - 10.3324/haematol.2018.196899

DO - 10.3324/haematol.2018.196899

M3 - Letter

C2 - 30381303

AN - SCOPUS:85063979631

SN - 0390-6078

VL - 104

SP - e151-e153

JO - Haematologica

JF - Haematologica

IS - 4

ER -

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study. Haematologica. 2019 Mar 31;104(4):e151-e153. doi: 10.3324/haematol.2018.196899